Immune-Image

CSA (Coordination and Support Action)

Immune-Image has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

01/10/2019 - 30/09/2024 (5 years)

VIEW PARTNERS >
View website

1 Stichting VUMC
2 Eberhard Karls Universität Tübingen
3 University of Cambridge
4 Westfälische Wilhelms-Universität Münster
5 Vrije Universiteit Brussel
6 Vlaams Instituut voor Biotechnologie
7 Academisch Ziekenhuis Groningen/
8 University Medical Centre Groningen
9 Vall d’Hebron Institute of Oncology
10 Vall d’Hebron Institute of Research
11 Atomic Energy and Alternative Energies Commission
12 Antaros Medical AB
13 Stichting Lygature
14 ttopstart BV
15 Lawrencium Legal BV
16 European Cancer Patient Coalition
17 F. Hoffmann-La Roche AG
18 Bayer AG
19 Janssen Pharmaceutica NV
20 Novartis Pharma AG
21 Pfizer Ltd.
22 ImagineAb Inc.
23 Takeda Pharmaceutical International AG

Why it matters?

The introduction of immunotherapeutic drugs for the treatment of cancer and inflammatory disease, where the drugs encourage the body’s own immune system to attack the disease, have had a significant impact. However, immunotherapies do not work for all patients. Immune-Image Project will develop methods to visualize and study the immune cells involved before, during, and after such treatments allowing selection of the right treatment for the right patient and at the right time. The information obtained about the immune cells and their activity during disease could be used to develop new drugs that might help those patients for which current immunotherapies are ineffective.

What ECPC does

ECPC supports communication and dissemination of the Immuno-Image project’s outcomes towards cancer patients and cancer organisations during the duration of the whole project.  This involves conveying information about the trials to confirm safety and to evaluate the clinical potential of novel immunotracers to ECPC cancer patient community and other relevant European patient organisations. ECPC involves multiple patient organisations who would benefit from the project outcomes.

Immune Imagine Brochures:

Video